Showing 5421-5430 of 5956 results for "".
- Kodiak Sciences Announces Data from Ongoing Phase 1b Study of KSI-301 in Patients With Wet AMD, DME and RVOhttps://modernod.com/news/kodiak-sciences-announces-data-from-ongoing-phase-1b-study-of-ksi-301-in-patients-with-wet-amd-dme-and-rvo/2477003/Kodiak Sciences announced promising safety, efficacy and durability data from its ongoing phase 1b study of its investigational therapy KSI-301 in patients with treatment-naïve wet age-related macular degeneration (AMD), diabetic macular edema (DME) and retinal vein
- Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-present-late-breaking-data-from-phase-3-studies-of-investigational-abicipar-pegol-in-wet-amd/2476996/Allergan and Molecular Partners announced 2-year data from the CEDAR and SEQUOIA clinical studies of investigational Abicipar in patients with wet age-related macular degeneration (AMD). In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains c
- Regenxbio Announces Additional Positive Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd/2476995/Regenxbio announced interim data from the ongoing phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). The results were presented by Jeffrey S. Heier, MD, Co-President and Director of Retina Research at Ophthalmic Consultants
- Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in US IDE Trial for iStent infinitehttps://modernod.com/news/glaukos-achieves-pipeline-milestone-with-completion-of-patient-enrollment-in-us-ide-trial-for-istent-infinite/2476990/Glaukos announced the completion of patient enrollment in its FDA Investigational Device Exemption (IDE) trial for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is designed for use in a standalone procedure to reduce elevated IOP in refractory glaucoma patients. I
- Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of AKB-9778 for Primary Open Angle Glaucomahttps://modernod.com/news/aerpio-pharmaceuticals-announces-interim-results-from-its-phase-1b-clinical-trial-of-akb-9778-for-primary-open-angle-glaucoma/2476991/Aerpio Pharmaceuticals announced interim results from its phase 1b clinical trial of a topical ocular formulation of AKB-9778 in development as a potential treatment for primary open angle glaucoma (POAG). The phase 1b study is an ongoing randomized, double-masked study designed to assess
- Harbour BioMed Announces Completion of Phase 2 Study in China of HBM9036 In Patients With Moderate-to-Severe Dry Eye Diseasehttps://modernod.com/news/harbour-biomed-announces-completion-of-phase-2-study-in-china-of-hbm9036-in-patients-with-moderate-to-severe-dry-eye-disease/2476993/Harbour BioMed (HBM) announced completion of a phase 2 study in China of HBM9036 (tanfanercept), a new, investigational TNF receptor-1 fragment, in adult patients with moderate-to-severe dry eye disease (DED). The study results, combined with previous results from HBM’s partner HanAll’s clinical
- Alcon Celebrates World Sight Day, Strengthens Commitment to Enhancing Global Access to Eye Carehttps://modernod.com/news/alcon-celebrates-world-sight-day-strengthens-commitment-to-enhancing-global-access-to-eye-care/2476983/Thousands of Alcon associates worldwide are participating in activities to support the advancement of eye health in honor of World Sight Day. To celebrate the occasion, the company announced a theme for the upcoming year, “Alcon: The Official Sponsor of 20/20,” which is designed to highlight its
- On World Sight Day, Allergan Launches National Campaign to Raise Awareness of Glaucomahttps://modernod.com/news/on-world-sight-day-allergan-launches-national-campaign-to-raise-awareness-of-glaucoma/2476984/Allergan announced a national education campaign called “My Glaucoma.” The campaign is designed to help people understand the burden of living with glaucoma and empower those with the disease and their caregivers to feel comfortable speaking with their doctor about a treatment
- Neurolign Acquires of Eye Diagnostic Technology Company Neuro Kineticshttps://modernod.com/news/neurolign-acquires-of-eye-diagnostic-technology-company-neuro-kinetics/2476981/Neurolign Technologies announced the acquisition of Neuro Kinetics of Pittsburgh, Pennsylvania, a provider of clinical eye-tracking and noninvasive neurofunctional diagnostic testing, delivering neurofunctional assessments. Terms of the deal were not disc
- Study Reports High Sensitivity in Diabetic Retinopathy Screening Using Smartphones and Automated-AI in Primary-Carehttps://modernod.com/news/study-reports-high-sensitivity-in-diabetic-retinopathy-screening-using-smartphones-and-automated-ai-in-primary-care/2476982/Nearly 50% of patients with diabetes fail to get an annual eye examination done even in the US and Europe. In many countries, less than 10% of patients referred to ophthalmologists by their primary-care physicians actually complete a dilated retinal examination. Technology can play a role in empo